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Trisomy 8 (+8), one of the most common chromosomal abnormalities found in 
patients with myelodysplastic syndromes (MDS), is occasionally seen in 
patients with otherwise typical aplastic anemia (AA). Although some studies 
have indicated that the presence of +8 is associated with the immune 
pathophysiology of bone marrow (BM) failure, its pathophysiology may be 
heterogeneous. We studied 53 patients (22 with AA and 31 with low-risk 
MDS) with +8 for the presence of increased 
glycosylphosphatidylinositol-anchored protein-deficient (GPI-AP-) cells, their 
response to immunosuppressive therapy (IST), and their prognosis. A 
significant increase in the percentage of GPI-AP- cells was found in 14 (26%) 
of the 53 patients. Of the 26 patients who received IST, including nine with 
increased GPI-AP- cells and 17 without increased GPI-AP- cells, 14 (88% 
with increased GPI-AP- cells and 41% without increased GPI-AP- cells) 
improved. The overall and event-free survival rates of the +8 patients with 
and without increased GPI-AP- cells at five years were 100% and 100% and 
59% and 57%, respectively. Examining the peripheral blood for the presence 
of increased GPI-AP- cells may thus be helpful for choosing the optimal 
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treatment for +8 patients with AA or low-risk MDS.  
 
Key words: Trisomy 8, bone marrow failure, GPI-AP- cells, 
immunosuppressive therapy  
  
Introduction 
Karyotypic abnormalities in patients with bone marrow failure are generally 
regarded as a hallmark of clonal hematopoietic disorders with the propensity 
toward transformation into acute myeloid leukemia (AML).  The incidence 
of cytogenetic abnormalities in aplastic anemia (AA) and myelodysplastic 
syndromes (MDS) is approximately 4% and 50 %, respectively (1, 2). Trisomy 
8 (+8), one of the most frequent chromosomal abnormalities found in patients 
with MDS, is occasionally seen in patients with otherwise typical AA (3-8). A 
recent study based on 2072 MDS patients showed that 8% of these patients 
had +8 in isolation (9). For both AML and MDS, +8 is listed in the 
‘intermediate-risk cytogenetic group’ (6, 9, 10). Several studies have shown 
that MDS patients with +8 are highly responsive to immunosuppressive 
therapy (IST) (3, 7, 11). However, +8 in AA patients is associated with an 
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increased risk of evolving into MDS/AML (5, 8). Thus, the prognostic 
significance of +8 in patients with AA or low-risk MDS remains unclear.  
Small populations of glycosylphosphatidylinositol-anchored 
protein-deficient (GPI-AP-) blood cells are often detected in the peripheral 
blood (PB) of patients with AA or low-risk MDS, such as refractory anemia 
(RA) and refractory cytopenia with multilineage dysplasia (RCMD) in the 
FAB classification (12-14). The GPI-AP- blood cells are detectable even in 
patients with BM failure that have chromosomal abnormalities, including +8 
(15-17). Parlier and Longo reported the first patient with GPI-AP- blood cells 
and + 8 who had ringed sideroblasts (18, 19). Our recent study showed a 
close association of del(13q) with the presence of increased GPI-AP- cells as 
well as a favourable response to immunosuppressive therapy (IST) (16). In 
patients with AA or RA possessing +8, the presence of GPI-AP- cells may 
affect response to IST as well as prognosis. To test this hypothesis, we 
analyzed clinical data of 53 BM failure patients with +8 whose blood cells 
were examined for the presence of GPI-AP- cells.  
 




This study included retrospective analysis of clinical records for 1228 BM 
failure patients: 733 with AA and 495 with low-risk MDS, including 286 with  
refractory cytopenia with unilineage dysplasia (RCUD), 149 with RCMD, 
and 60 with unclassified MDS (MDS-U). In all patients, blood samples were 
examined for the presence of GPI-AP- granulocytes and erythrocytes at our 
laboratory between May 1999 and July 2010. BM smear slides and trephine 
biopsy specimens were reviewed by two independent hematologists. BM 
cellularity was expressed as the percentage of BM volume occupied by 
hematopoietic cells in the trephine biopsy specimens. Hypocellular marrow 
was defined as <30% cellularity in patients <70 years, or <20% cellularity in 
patients ≥70 years (20). Chromosomal analysis was performed using the 
G-banding method and the presence of +8 clones were confirmed by 
fluorescent in-situ hybridization (FISH) when the number of +8 revealed by 
G-banding was less than or equal to two. The results of G-banding were 
described according to the International System for Human Cytogenetic 
Nomenclature (ISCN) (21). The ethics committee of Kanazawa University 
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Graduate School of Medical Science approved the study protocol, and all 
patients provided informed consent prior to sampling.  
 
Therapy and response criteria 
Horse anti-thymocyte globulin (ATG, Lymphoglobulin, Genzyme, Cambridge, 
MA, USA) in combination with cyclosporine (CsA) was given to patients with 
Severe aplastic anemia (SAA). Four to 6 mg/kg of CsA was administered to 
patients with moderate AA (MAA) or MDS. Trough levels of CsA were 
maintained between 150 and 250 ng/mL. Six patients (4 with AA and 2 with 
MDS) received 10 to 20 mg/day of metenolone acetate in addition to CsA. 
Responses to IST were defined according to the established criteria (22, 23).  
 
Monoclonal antibodies  
Monoclonal antibodies (mAbs) used for flow cytometry were FITC-conjugated 
anti-CD59 (P282E, IgG2a; Beckman Coulter, Brea, CA, USA), 
FITC-conjugated anti-CD55 (IA10, IgG2a; BD Pharmingen, San Diego, CA, 
USA), PE-conjugated anti-CD11b/Mac-1 (ICRF44, IgG1; BD Pharmingen) 
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and PE-conjugated anti-glycophorin A (JC159, IgG1; Dako, Glostrup, 
Denmark).  
 
Detection of GPI-AP- cells by flow cytometry  
All blood samples were analysed within 24 hours of collection to avoid false  
positive results due to cell damage. Staining with each mAb was performed 
according to the lyse-stain protocol as previously described (24, 25). The 
presence of CD55−CD59−glycophorin A+ erythrocytes at the level of ≥0.005% 
and/or CD55−CD59−CD11b+ granulocytes at the level of ≥0.003% was defined 
as an abnormal increase (“positive”) based on results obtained from 183 
healthy individuals (26). With careful handling of samples and elaborate 
gating strategies, cut-off values can be lowered to these levels without 
producing false positive results (24, 27, 28).  
 
Statistical analysis  
Prevalence of increased GPI-AP- cells among different patient populations 
was compared using the chi-square test. The Kaplan-Meier method and the 
Cox proportional hazards model were used to estimate time-to-event 
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analysis. Overall survival (OS) was calculated in months from date of 
diagnosis until date of death or last follow-up. Event-free survival (EFS) was 
defined as the time from diagnosis to AML evolution or death. Two-sided 
P-values were calculated, and P<0.05 was considered statistically significant. 
All statistical analyses were performed using the EZR software package 
(Saitama Medical Center, Jichi Medical University), a graphical user 
interface for R (The R Foundation for Statistical Computing, version 
2.13.0) (29).  
 
Results 
Incidence of BM failure patients with +8 
Of 754 patients with AA 22 (2.9%) possessed +8; instead, of 483 patients with 
low-risk MDS 31 (6.4%) possessed +8. Their clinical features are summarized 
in Table I. The median age of patients with +8 was 61, and BM was 
hypocellular in 32 patients, normocellular in 15, and hypercellular in six. 
Thirty-five patients had trisomy 8 alone (+8 alone), while 18 patients had 
additional chromosomal abnormalities (+8 others). The median percentage of 
+8 cells in karyotyped cells was 15%. Diagnoses of 31 MDS patients 
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according to the 2008 WHO classification included nine patients with RCUD, 
16 with RCMD, and six with MDS-U. None of the patients with +8 had 
ringed sideroblasts. All MDS patients were classified as Int-1 according to 
the International Prognostic Scoring System (IPSS).  
 
Prevalence of patients possessing increased GPI-AP- cells 
As shown in Table 1, 14 (26.4%) of patients with +8 had GPI-AP- cells that 
accounted for 0.003% to 39.124% (median, 0.049%) of granulocytes. One 
patient who possessed 0.002% GPI-AP- granulocytes was judged positive 
because 0.026% of the patent's erythrocytes were GPI-AP- cells 
(Supplementary Fig. 1). None of the patients evolved into clinical PNH 
during the observation period of 2-10 years. The prevalence of increased 
GPI-AP- cells was lower than that (43%) in 937 BM failure patients (637 with 
AA and 300 with MDS) with normal karyotype (16). Of 22 AA patients with 
+8 nine (41%) had increased GPI-AP- cells; instead, of 31 low-risk MDS 
patients with +8 five (16%) had increased GPI-AP- cells. (P =0.04)  
 
Response to IST in BM failure patients with +8 
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Twenty-six patients (49%) were treated with IST and 25 of these had 
evaluable responses. IST included CsA alone in 15 patients, CsA and ATG in 
five patients, and CsA and metenolone acetate in six patients. The overall 
response rate to IST in the +8 patients was 56% (14/25 patients). Of 16 AA 
patients with +8 treated with CsA and ATG (5) or CsA±metenolone acetate 
(11), nine (56%) responded. Nine MDS patients with +8 were treated with 
CsA±metenolone acetate and five (56%) improved (P =0.97). Of 8 patients 
positive for GPI-AP- cells treated with IST 7 (88%) responded; instead, of 17 
patients negative for GPI-AP- cells 7 (41%) responded (P =0.03). Comparison 
of patients with +8 with 141 BM failure patients (120 with AA and 21 with 
MDS) with normal karyotypes that were included in our previous study (16) 
showed that +8 patients had lower response rates to IST than patients with 
normal karyotypes; 56% in +8 AA patients vs. 81% in normal karyotype AA 
patients (P =0.03) and 56% in +8 MDS patients vs. 62% in normal karyotype 
MDS patients (P =0.75) although the differences were not statistically 
significant in MDS patients (16).  
 
Prognosis in BM failure patients with +8 
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None of the 14 +8 patients with increased GPI-AP- cells progressed to 
advanced MDS or AML during the follow-up period of 2 to 239 months 
(median, 67 months). On the other hand, five of the 39 +8 patients without 
GPI-AP- cells developed AML. The five-year OS and EFS rates of the 53 
patients with +8 patients were 69.4% and 68.1%, respectively (Fig. 1A).  
The five-year OS/EFS rates of +8 patients with increased GPI-AP- cells were 
100%/100%; instead, the five-year OS/EFS rates of +8 patients without 
increased GPI-AP- cells were 58.6%/56.9% (P=0.0347, P=0.0269, respectively; 
Fig. 1B). The five-year OS rates of +8 patients with +8 alone were 81.7%; 
instead, the five-year OS rates of +8 patients with +8 with other 
abnormalities were 45.5% (P = 0.0196; Fig. 1C). When age, gender, diagnosis, 
cellularity, clone size, karyotype complexity, and GPI-AP- cells were included 
in the multivariate analysis, higher age (60 years or older) and the absence 
of GPI-AP- cells represented independent negative predictors for OS (Table 
2).  
To further evaluate the significance of GPI-AP- cells in +8 patients, the 
five-year OS rates of BM failure patients with +8 were compared with those 
of 246 BM failure patients (179 with AA and 67 with MDS) with normal 
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karyotype that were included in our previous study (16). There was no 
significant difference in the survival rates between the two groups with 
increased GPI-AP- cells (100% vs 92.7% P = 0.914; Fig. 2A) while the survival 
rate of +8 patients without increased GPI-AP- cells (58.6%) was lower than 
that of patients with normal karyotype not possessing increased GPI-AP- 
cells (79.5%, P = 0.0007; Fig. 2B). 
 
Discussion 
The current retrospective study of a large number of BM failure patients 
revealed distinctive clinical features of BM failure patients with +8 
abnormalities. Of the 483 patients with low-risk MDS, 31 (6.6%) possessed 
+8, which was comparable to the 8% reported in a recent study of 2072 MDS 
patients (2). That study did not provide any detailed diagnoses of the 
patients with +8. The present study detected GPI-AP- cells in 26.4% of 
patients with +8, and the prevalence of increased GPI-AP- cell percentages 
was higher in AA patients (41%) than in those with low-risk MDS (16%). 
This study is the first to reveal the prevalence of increased GPI-AP- cell 
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percentages based on a large number of AA and low-risk MDS patients with 
+8.  
Approximately half of the patients with +8 were treated with IST, with 
an overall response rate of 56%. The relatively high response rate was 
probably achieved because IST was only administered to patients who had 
clinical features associated with a good response to IST, such as a short 
disease duration and the presence of thrombocytopenia with decreased 
megakaryocytes (30). The response rates were similar between AA (56%) 
and low-risk MDS patients (56%). However, there was a significant 
difference in the response rate between the patients with and those 
without increased GPI-AP- cells (88% vs. 41%).  
Consistent with our current data, several studies demonstrated that AA 
and MDS patients with +8 are likely to respond to IST (3, 7, 11). There may 
thus be a common mechanism underlying the preferential commitment of 
hematopoietic progenitor clones with +8 in immune-mediated BM failures. 
One study revealed an increased expression of the WT1 gene by BM 
mononuclear cells from MDS patients with +8, which may elicit specific T 
cell responses to WT1 peptides and lead to the suppression of non +8 
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hematopoietic progenitor cells by bystander effects of activated T cells (11). 
The same group proposed that BM CD34+ cells of + 8 patients exhibit 
resistance to apoptosis and increased myc expression as the mechanisms 
underlying the proliferative advantage of +8 clones (31). We were unable to 
examine WT1 gene expression and the number of WT1-specific T cells in our 
+8 patients who were responsive to IST. However, we believe that the specific 
immune responses to +8 clones may not be the main mechanism underlying 
the immune-mediated BM failure, for the following reasons: First, if the 
immune response is directed against +8 clones, successful T-cell suppression 
by IST should lead to the expansion of the abnormal clone. In reality, the 
changes in the percentage of +8 clones in patients responding to IST were 
highly variable and did not show a steady increase (Supplementary Fig 2). 
Second, the likelihood of responding to IST was determined by the presence 
of GPI-AP- cells, not by the +8 clones; the +8 patients did not respond better 
to IST than patients with a normal karyotype (56% of AA patients with +8 vs. 
81% of AA patients with a normal karyotype and 56% of MDS patients with 
+8 vs. 62% of MDS patients with a normal karyotype). Third, leukocytes with 
copy number- neutral loss of heterozygosity in the short arm of chromosome 
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6 (6pLOH) should be detected in patients with +8 if they are targets of 
cytotoxic T-cell attacks, based on our previous study showing that leukocytes 
with 6pLOH are detectable in 13% of AA patients (32). However, none of the 
six patients with +8 studied in the present population had leukocytes with 
6pLOH (data not shown).  
The IPSS classifies +8 as an intermediate risk factor for the progression 
of MDS (10, 33). The prognostic significance of +8 was confirmed by recent 
studies that involved MDS with at least 5% blasts (34). However, its 
significance in patients with AA and low risk MDS with less than 5% blasts 
has not been extensively studied. In contrast to previous reports (3, 11), 
this study revealed that AA and MDS with less than 5% blasts comprise a 
subset of patients with a propensity to evolve into AML. Recently, Schanz 
et al. studied 2902 MDS patients including 133 patients with +8 who had a 
median blast percentage of 4% in their BM and revealed that the median 
overall survival of the 133 patients was 23 months (6). However, this study 
included 1190 (42.7%) patients with blast percentages>5% in the BM. The 
median overall survivals in our 53 patients with +8 were 78 months in AA 
and 43 months in MDS patients. This study is the first to estimate the 
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overall survival in AA and low-risk MDS patients with +8 whose blast 
percentage in the BM is less than 5% based on a large number of patients.  
On the other hand, the finding that the five-year EFS of +8 patients with 
an increased GPI-AP- cell percentage was 100% suggests that this subset of 
+8 BM failures is a benign type of BM failure similar to that of AA patients 
with normal karyotypes possessing increased GPI-AP- cells rather than a 
clonal disorder associated with a high risk of developing AML. The median 
age (66 years vs 59 years) and prevalence of hypercellular marrow (14% vs 
10%) in patients with and without GPI-AP- cells were similar.  
By comparing clinical courses between +8 patients and normal 
karyotype patients, both patient groups with increased GPI-AP- cells 
proved to have good prognosis regardless of the presence of +8, while in 
patients without increased GPI-AP- cells, the survival rate of +8 patients 
was significantly lower than that of patients with normal karyotype, 
strongly suggesting the importance of detecting GPI-AP- cells in predicting 
the prognosis of +8 patients. The WHO 2008 classification defined +8 as an 
intermediate-risk abnormality of MDS. The BM failure patients with +8 
possessing an increased number of GPI-AP- cells may therefore be treated 
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in an inappropriate way such as with hypomethylating agents and 
allogeneic stem cell transplantation from unrelated donors. Therefore, our 
present findings suggest that it is important to determine if increased 
GPI-AP- cells are detectable when BM failure patients are found to have +8. 
The significance of detecting GPI-AP- cells in +8 patients needs to be 
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Table 1. Clinical features of bone marrow failure patients with trisomy 8 
UPN Age Sex Dx Cellul
arity 
IPSS % of Other 
abnorm
alities 
% GPI-AP- % GPI-AP- GPI-AP- 
cells 
Treatment Response Outcome Cause of death AML 
transformation +8 cells  Granulocytes Erythrocytes 
1 69 M SAA Hypo NE 5 - 0.034 0.038 Positive ATG+CsA PR Death Infection No 
2 21 F SAA Hypo NE 25 + 39.124 2.106 Positive ATG+CsA PR Alive  No 
3 50 F SAA Hypo NE 15 - 0.002 0.026 Positive ATG+CsA→BMT NR Alive  No 
4 26 F SAA Hypo NE 10 - 0 0 Negative ATG+CsA PR Death Infection No 
5 16 M SAA Hypo NE 20 - 0 0 Negative ATG+CsA→BMT NR Death Infection No 
6 26 M SAA Hypo NE 15 - 0 0 Negative Allo-BMT NA Death Infection Yes 
7 68 M SAA Hypo NE 5 - 0.002 0.002 Negative Allo-BMT NA Alive  Yes 
8 46 F SAA Hypo NE 55 + 0 0.004 Negative CsA→Allo-BMT NR Death GVHD Yes 
9 66 F MAA Hypo NE 10 - 0.007 0 Positive CsA PR Death Infection No 
10 61 M MAA Hypo NE 10 - 6.201 8.657 Positive CsA PR Alive  No 
11 50 M MAA Hypo NE 10 - 0.033 0.039 Positive CsA+AS PR Alive  No 
12 71 M MAA Hypo NE 10 - 0.049 0.092 Positive CsA+AS PR Alive  No 
13 68 M MAA Hypo NE 5 - 0.363 0.045 Positive No treatment NA Alive  No 
14 65 F MAA Hypo NE 80 - 0.64 0.327 Positive No treatment NA Alive  No 
15 69 M MAA Hypo NE 15 - 0 0.001 Negative CsA NR Death Lung Cancer No 
16 35 M MAA Hypo NE 5 - 0 0 Negative CsA NR Alive  No 
17 79 M MAA Hypo NE 45 + 0 0 Negative CsA NR Alive  No 
18 71 F MAA Hypo NE 30 - 0 0.002 Negative CsA PR Alive  No 
19 10 M MAA Hypo NE 80 - 0 0.004 Negative CsA+AS NR Death Pneumonia No 
20 33 M MAA Hypo NE 35 - 0 0 Negative CsA+AS PR Alive  No 
21 60 F MAA Hypo NE 25 - 0 0.001 Negative No treatment NA Alive  No 
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22 31 F MAA Hypo NE NE - 0 0 Negative No treatment NA Alive  No 
23 42 F RCUD(RA) Normo Int-1 50 + 0 0 Negative CsA NR Death Heart failure No 
24 87 F RCUD(RA) Hypo Int-1 35 + 0 0.003 Negative CsA+AS NR Death Infection No 
25 70 M RCUD(RA) Hyper Int-1 5 - 0 0 Negative CsA+AS NR Death Heart failure No 
26 81 M RCUD(RA) Normo Int-1 5 + 0 0 Negative AS,VitK Progression Death Progression No 
27 51 M RCUD(RA) Hypo Int-1 70 + 0 0 Negative Allo-BMT NA Alive  No 
28 56 F RCUD(RA) Normo Int-1 85 - 0 0.001 Negative PSL SD Alive  No 
29 75 M RCUD(RA) Normo Int-1 15 - 0 0.001 Negative AS Progression Death Progression No 
30 72 F RCUD(RA) Hypo Int-1 75 + 0 0 Negative No treatment NA Alive  No 
31 66 F RCUD(RA) Normo Int-1 10 + 0 0.01 Negative No treatment NA Alive  No 
32 81 M RCMD Hyper Int-1 5 - 0.034 0 Positive NA NA Alive  No 
33 88 F RCMD Hyper Int-1 50 - 0.142 0.23 Positive AS PR Alive  No 
34 18 F RCMD Hypo Int-1 55 + 0.003 0.008 Positive Allo-PBSCT NA Alive  No 
35 59 F RCMD Hyper Int-1 5 - 0.001 0.001 Negative CsA CR Alive  No 
36 65 M RCMD Hypo Int-1 5 - 0 0.001 Negative CsA HI-1 Alive  No 
37 28 F RCMD Normo Int-1 20 - 0 0 Negative CsA HI-1 Alive  No 
38 61 F RCMD Hyper Int-1 100 - 0 0 Negative CsA HI-2 Death Bleeding No 
39 59 M RCMD Hypo Int-1 35 + 0.001 0.003 Negative CsA Progression Death Progression Yes 
40 51 F RCMD Hypo Int-1 13 + 0 0.002 Negative PSL SD Death Infection No 
41 89 M RCMD Normo Int-1 50 - 0 0 Negative AraC Progression Death Progression No 
42 72 M RCMD Normo Int-1 10 + 0 0 Negative VitK NA Death Pneumonia No 
43 50 F RCMD Normo Int-1 NE - 0 0.001 Negative AS,VitK SD Alive  No 
44 77 F RCMD Normo Int-1 10 + 0 0.003 Negative AS Progression Death Progression Yes 
45 7 M RCMD Normo Int-1 10 - 0 0.002 Negative Allo-BMT NA Death TMA No 
46 63 F RCMD Normo Int-1 NE + 0 0 Negative No treatment NA Death Progression No 
47 56 F RCMD Normo Int-1 40 - 0 0.002 Negative No treatment NA Alive  No 
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48 70 F MDS-U Hypo Int-1 5 + 0.005 0.023 Positive CsA CR Alive  No 
49 81 M MDS-U Hypo Int-1 95 + 6.851 0.272 Positive CsA NA Alive  No 
50 75 M MDS-U Hyper Int-1 5 - 0 0 Negative AS HI-3 Death Infection No 
51 77 M MDS-U Normo Int-1 35 + 0 0 Negative AS,VitK Progression Death Progression No 
52 34 F MDS-U Hypo Int-1 NE - 0 0 Negative Allo-PBSCT NA Alive  No 
53 55 F MDS-U Normo Int-1 45 - 0 0 Negative No treatment NA Alive  No 
Medi
an 
61         
15 










Table 2. Results of multivariate analysis of prognostic factors for overall survival of patients with BM failure with trisomy 8 
Variable Categories 
BMF with trisomy 8 
Hazard ratio  
(95% CI) 
P-value 
Age ≥60 years vs. <60 years 3.9 (1.1–13.6) <0.05 
Sex Male vs. female 1.5 (0.6–4.2) 0.42 
Diagnosis AA vs. MDS 1.3 (0.3–5.8) 0.74 
Cellularity Hypocellular vs. others 0.5 (0.1–1.9) 0.31 
Karyotype complexity 8+ alone vs. 8+ others 0.4 (0.1–1.3) 0.12 
Clone size (% of +8 cells) ≥15% vs. <15% 0.5 (0.2–1.3) 0.16 
GPI-AP- cells Positive vs. negative  0.1 (0.02–0.7) <0.05 
GPI-AP- cells: glycosylphosphatidylinositol-anchored protein-deficient blood cells; AA: aplastic anemia;  




Figure.1. Overall and event-free survival rates of BM failure patients with 
trisomy 8  
(A) Five-year overall survival (OS) and event-free survival (EFS) rates of +8 
patients. (B) Five-year OS and EFS rates of +8 patients with and without 
increased GPI-AP- cells. (C) Five-year OS and EFS rates of +8 patients with 
+8 alone and +8 with other abnormalities (8+ others). The EFS was defined 
as the time from diagnosis to AML evolution or death.   
Figure.2. Overall survival rates of BM failure patients with trisomy 8 and 
normal karyotype  
(A) Five-year overall survival (OS) rates of +8 patients and normal karyotype 
patients with increased GPI-AP- cells. (B) Five-year OS rates of +8 patients 





Supplementary Figure 1.  
One patient who possessed 0.002% GPI-AP- granulocytes was judged positive 
because 0.026% of the patent's erythrocytes were GPI-AP- cells.   
Supplementary Figure 2.   
Changes in the proportion of +8 cells for six patients. The percentage of +8 
clones revealed by G-banding increased in three patients (UPN3, 20, 33) and 
decreased in two patients (UPN2,9) after successful IST. 
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